Cargando…
Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
Background: Hyperprogressive disease (HPD) rate in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI) was determined using tumor growth kinetics (TGK) and compared with rapidly progressive screen-failure (SF) patients. The impact of TGK on outcomes...
Autores principales: | Karabajakian, Andy, Garrivier, Thibaut, Crozes, Carole, Gadot, Nicolas, Blay, Jean-Yves, Bérard, Frédéric, Céruse, Philippe, Zrounba, Philippe, Saintigny, Pierre, Mastier, Charles, Fayette, Jérôme |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210015/ https://www.ncbi.nlm.nih.gov/pubmed/32405337 http://dx.doi.org/10.18632/oncotarget.27563 |
Ejemplares similares
-
Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma
por: Karabajakian, Andy, et al.
Publicado: (2022) -
Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
por: Foy, Jean-Philippe, et al.
Publicado: (2022) -
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
por: Varnier, Romain, et al.
Publicado: (2021) -
Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab
por: Sama, Shashank, et al.
Publicado: (2019) -
Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
por: Faure, Marjorie, et al.
Publicado: (2018)